Pharma BD Deal Intelligence
Merger produced one real blockbuster (Radicava) but Mitsubishi Chemical ultimately concluded pharma didn't belong in a chemicals conglomerate and sold the whole unit off in 2025 at roughly the price it paid in 2007.
Full analysis, sources & comparables →Tanabe characterized the rationale as responding "to the competitive environment surrounding the pharmaceutical market" and the need to "survive intensifying…
"On October 1, 2007, Tanabe Seiyaku Co., Ltd. merged with Mitsubishi Pharma to form Mitsubishi Tanabe Pharma" as a consolidated subsidiary of Mitsubishi…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Merger to form Mitsubishi Tanabe Pharma effective Oct 1, 2007. Source: Mitsubishi Tanabe Pharma corporate, Wikipedia.
Merger produced one real blockbuster (Radicava) but Mitsubishi Chemical ultimately concluded pharma didn't belong in a chemicals conglomerate and sold the whole unit off in 2025 at roughly the price it paid in 2007.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mitsubishi Pharma Corp. / Tanabe Seiyaku Co. Ltd. (this deal) | 2007 | $4.3B | 44 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| Reckitt Benckiser plc / Adams Respiratory Therapeutics Inc. | 2007 | $2.3B | 82 |
| Mylan Laboratories Inc. / Merck Generics (Merck KGaA) | 2007 | $6.7B | 81 |
← Browse all deals · How we score deals
More: 2007 deals